I wrote in this blog recently of the many suits filed in the past few years against Johnson & Johnson alleging that its famous baby powder products cause cancer in women. That fight remains ongoing. But J&J’s legal woes over its products aren’t in any way limited to over-the-counter consumer goods like talc or baby powder. Many of the lawsuits it has faced involve its prescription drugs.
One of those drugs is Levaquin, which was developed by J&J as a type of antibiotic. Levaquin belongs to the fluoroquinolone class of antibiotics, and was marketed by J&J to treat relatively minor infections, such as sinus infections and urinary tract infections (UTI’s.) Sounds admirable enough, except that plaintiffs’ suits in several states, including Pennsylvania and New Jersey, allege that the giant health and pharmaceutical company very aggressively marketed Levaquin, while knowing that the antibiotic could cause a dangerous medical condition called peripheral neuropathy – a very serious nerve disorder. Often times, this dangerous disorder can become permanent – resulting in loss of nerve sensation and partial paralysis. Many of these suits allege not only that Levaquin is a defective medical product, but that J&J knew about this while it was marketing the drug to doctors, and intentionally failed to warn doctors about the risks of neuropathy to their patients. Continue reading